23 April 2014
Hello. I'm Dr. Roger Steinert, Chair of Ophthalmology and Director of the Gavin Herbert Eye Institute at the University of California, Irvine. I just returned from the World Ophthalmology Congress, held this year in Tokyo, Japan, and had the opportunity to participate in several sessions on presbyopia treatments with intracorneal inlays.
28 March 2014
Syndax Pharmaceuticals raised about $27 million in private financing last year to gear up for a late-stage clinical trial. Now, on the doorstep of that lengthy, 600-patient study, the Waltham, MA-based company is looking to Wall Street to get it to the finish line.
27 March 2014
Syndax Pharmaceuticals, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of shares of its common stock. All shares of common stock to be sold in the offering will be offered by Syndax. The number of shares to be offered and the price range for the offering have not yet been determined.
20 March 2014
Entinostat is being investigated in patients with advanced hormone receptor-positive breast cancer by the ECOG-ACRIN Cancer Research Group in its latest trial, E2112.
17 February 2014
A hydrogel corneal inlay improved near, intermediate and distance vision, regardless of preoperative refractive error, according to a study presented at Hawaiian Eye 2014.
03 February 2014
Syndax Pharmaceuticals, Inc., today announced the appointment of distinguished breast cancer specialist, George W. Sledge, Jr., M.D., to its board of directors as an independent director. Dr. Sledge is currently professor and chief of medical oncology at Stanford University Medical Center.
13 January 2014
Elects Two Life Sciences Veterans, Enrique J. Carrazana, M.D. and Jay P. Shepard, to Its Board of Directors; Appoints Edward F. Smith as Chief Financial Officer.
03 November 2013
Syndax Pharmaceuticals, Inc. today announced the promotion of John S. Pallies to chief financial officer from vice president, finance and administration, and co-founder Peter Ordentlich, Ph.D., to chief technology officer from vice president, translational medicine. Both appointments are effective Nov.1, 2013.
21 October 2013
ReVision Optics is upping the technological game with vision improvement devices and technology. The company's Raindrop Near Vision microscopic hydrogel inlay is designed to treat patients with presbyopia, the loss of near vision in patients when they reach middle age and typically need reading glasses. CEO John Kilcoyne said doctors can now also use RainDrop in patients receiving a separate procedure to correct their distance vision.
21 October 2013
This year's crop endured the struggles many startups face and came out ahead. They've attracted substantial funding from major investors in a tough market, proving the worth of their products. Many are also already in--or close to--market with their signature products, a sign of stability that draws investor commitments much more these days than companies on the earlier side of development.
29 January 2020
28 January 2020
28 January 2020
27 January 2020